DOP81: Unaffected ileal transcriptomics in Crohn's disease is associated with the response to anti-TNF therapyECCO’23 Copenhagen 2023
DOP86: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: A phase 3, randomised, placebo-controlled study (LIBERTY-CD).ECCO’23 Copenhagen 2023
DOP87: The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study ResultsECCO’23 Copenhagen 2023
DOP88: Understanding the molecular mechanisms of anti-TNF treatment failure: Whole blood DNA methylation changes associated with primary non-response to anti-TNF treatment in patients with Crohn’s diseaseECCO’23 Copenhagen 2023
DOP89: Impact of biologics on the risk of early postoperative complications in Crohn's disease: a French nationwide studyECCO’23 Copenhagen 2023
DOP90: The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumabECCO’23 Copenhagen 2023
OP01: Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn’s diseaseECCO’23 Copenhagen 2023
OP02: Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximabECCO’23 Copenhagen 2023
OP03: Highly stable epigenome-wide peripheral blood DNA methylation signatures accurately predict endoscopic response to adalimumab, vedolizumab and ustekinumab in Crohn’s disease patients: The EPIC-CD studyECCO’23 Copenhagen 2023
OP04: Efficacy of upadacitinib in ulcerative colitis: A phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patientsECCO’23 Copenhagen 2023
OP05: High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitisECCO’23 Copenhagen 2023
OP06: Multiomic interrogation of the epithelium in active Ulcerative Colitis reveals dysregulated myeloid cells associated with non-response to anti-Tumour Necrosis Factor therapy.ECCO’23 Copenhagen 2023
OP07: Absolute and relative risks of kidney and urological complications in patients with Inflammatory Bowel DiseaseECCO’23 Copenhagen 2023
OP08: Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trialECCO’23 Copenhagen 2023
OP09: Long-term Colectomy rates of Ulcerative Colitis over 40-year of Different Therapeutic eras – Results from a Western Hungarian Population-based Inception Cohort between 1977–2020ECCO’23 Copenhagen 2023
OP10: Proctocolectomy with permanent ileostomy is associated with better transplant-free survival in patients with primary sclerosing cholangitis: a retrospective cohort studyECCO’23 Copenhagen 2023